Galderma to Highlight Latest Science and Innovation Across Its Product Portfolio at the 2022 AAD Annual Meeting

News provided by Galderma
March 28, 2022 11:45 Korea Standard Time

FORT WORTH, TEXAS--(Business Wire / Korea Newswire) March 28, 2022 -- Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will be attending the 2022 American Academy of Dermatology Annual Meeting to showcase its latest approved and investigational product updates. This includes clinical data presentations at its product theaters, advisory boards, and booth activities onsite as AAD returns in-person once more.

“We are excited to attend AAD to connect with the dermatology community and showcase our latest innovation and data across our complete dermatology portfolio,” said Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma. “Our presence underscores our commitment to developing and bringing to market dermatological solutions to address every skin need.”

A considerable amount of new data will be presented during the AAD Congress in the form of abstracts and oral presentations for nemolizumab, a first-in-class investigational monoclonal antibody directed against the interleukin-31 (IL-31) receptor, under clinical development for the treatment of atopic dermatitis and prurigo nodularis.

The data for prurigo nodularis include efficacy data of nemolizumab and its impact on itch and sleep disturbance. An additional seven abstracts look at a variety of aspects of the disease including its prevalence, current treatment practices and the effect of the disease on sleep, mental health disorders and gastrointestinal and hepatobiliary diseases. Three abstracts in atopic dermatitis look at the safety and efficacy of nemolizumab in adolescents and the impact of nemolizumab according to EASI and Scorad components.

Galderma will present thirteen study abstracts regarding its investigational monoclonal antibody that targets the IL-31 receptor, nemolizumab. Data comes from Phase 2 studies and real-world evidence. More details on Galderma’s activities can be found below.

(To view the table, please visit https://bwnews.pr/3DfdArF)

Additionally, Galderma will be hosting four product theaters to discuss new research findings across our portfolio:

(To view the table, please visit https://bwnews.pr/3DfdArF)

A series of Speakers Forum talks will be held on the Galderma booth #1117.

(To view the table, please visit https://bwnews.pr/3DfdArF)

For more information on IL-31 and its role in the pathophysiology of atopic dermatitis and prurigo nodularis, visit www.IL31role.com.

About atopic dermatitis
Atopic dermatitis (AD) is a chronic, debilitating inflammatory skin disease, characterized by diffuse skin lesions and constant, severe disruptive itch.[1],[2] Reported prevalence of AD varies greatly, ranging from 1% to 25% of the population depending on the geography and age range.[3] AD can have a profound impact on patients’ quality of life, leading to sleep difficulties, psychological complications and causing secondary skin infections (bacterial and viral).[4]

About prurigo nodularis
Prurigo nodularis (PN) is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated intense unrelenting itch.[5] While PN can occur at any age, it is most likely to affect people between the ages of 40 and 69, frequently leading to severe impairment in quality of life.[6]

The global prevalence of PN is not well known as there are few studies describing the epidemiology of the condition. In the U.S., the latest estimate is that PN affects 52.9 people in every 100,000.[4] In the European context, rates of between 0.65 and 11.1 per 10,000 population have been reported. In addition to natural variation, this relatively wide range of estimates is partly due to differences in case definition and the representativeness of the study populations.[6]

About nemolizumab
Nemolizumab is an investigational agent under clinical development for the treatment of atopic dermatitis and prurigo nodularis and its safety and efficacy have not been fully evaluated by any regulatory authority.

About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com/us.

References

[1] Langan S. et al. Atopic dermatitis. The Lancet. 2020;396(10247):345-360. DOI: https://doi.org/10.1016/S0140-6736(20)31286-1
[2] Weidinger S. et al. Atopic dermatis. Nature Reviews. 2018. DOI: 10.1038/s41572-018-0001-z
[3] Silverberg, J, I. Public Health Burden and Epidemiology of Atopic Dermatitis.283-289. 2017.
[4] Galderma. Data on File. To be presented at AAD 2022.
[5] Galderma. Data on File. Press Release. Galderma presents new nemolizumab data at EADV. 2021.
[6] Morgan LI. Christopher. Epidemiology of prurigo nodularis in England. Accepted for publication in British Journal of Dermatology
[7] Saleem M. et al. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatolog Treat. 2017;28(7):591-599. DOI: 10.1080/09546634.2017.1290205

View source version on businesswire.com: https://www.businesswire.com/news/home/20220325005215/en/

Website: http://www.galderma.com

Contact

Galderma
Shannon Iwaniuk
Director, U.S. Communications
+1 720 308 1336


Rachel Mooney
Director, Global Franchise Communications
+41 58 455 85 41 /+41 76 261 64 41

This is a news release distributed by Korea Newswire on behalf of this company.